Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Lancet Respiratory Medicine
Oct 2021 Volume 9 Number 10 p1077-1202, e96-e103
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Tracy J Ruckwardt, get al; VRC 317 study team